A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).
about
Bortezomib for the treatment of mantle cell lymphoma: an updateMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsTrial Watch: Proteasomal inhibitors for anticancer therapyA phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Bortezomib in multiple myeloma: systematic review and clinical considerations.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Pharmacological targets in the ubiquitin system offer new ways of treating cancer, neurodegenerative disorders and infectious diseases.Hepatitis E virus replication requires an active ubiquitin-proteasome system.Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedsideBortezomib in mantle cell lymphoma: comparative therapeutic outcomesInhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.From bortezomib to other inhibitors of the proteasome and beyond.Bortezomib for the treatment of non-Hodgkin's lymphomaEmerging agents for the treatment of mantle cell lymphoma.Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies.Novel agents in mantle cell lymphoma.Bortezomib in the treatment of mantle cell lymphoma.The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?How to manage mantle cell lymphoma.Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.Inhibition of O-GlcNAcase sensitizes apoptosis and reverses bortezomib resistance in mantle cell lymphoma through modification of truncated Bid.Positioning of proteasome inhibitors in therapy of solid malignancies.Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations.A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma.Velcade combinations in mantle cell lymphoma: are we learning anything?Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P2860
Q26738940-14D6F98D-7E1E-4D46-993E-C9EEFDFFCB1CQ28075606-04212431-FFD6-434D-9CD5-3EB4ED069B73Q28082910-A30AC0D2-BEF7-49BD-A5F5-3EB4D24C35A8Q33409608-0BE92D9C-5D84-4517-BAD5-0DEDB61F5D5DQ33586239-092A47BF-5EDF-4390-A7E1-0B1B9FCA0C44Q33982728-DB01CCFD-3240-4FBC-B51D-A0E5B6F93450Q34788381-135DCC9A-2CF7-4FE4-93A3-57F2E8415AFEQ35559055-EC69ABB0-7665-4194-A3CB-FA3CA7875A3AQ35943360-506D81A2-343E-4F3D-96DC-3F5E9D4391E7Q35989980-61E6FDF0-6228-4A72-9726-545DE1D6BA9BQ36278006-AB5B5B6A-6A91-487A-9A5B-8462588BFFE5Q36546004-C97AD479-0443-4F63-B52D-4B34151CDC5AQ36852277-760C981A-1BEF-46D3-BDE5-AEB7D0091BCCQ36868056-EA249703-3AB9-4815-82CA-04FA038C4F72Q38055498-D517261C-DE87-46D7-AEC5-9600A8CECA18Q38122437-670B92D2-CCD2-4102-809A-E172795EDBFDQ38516704-9D5988CA-1D65-4E85-B420-2C6A49FFFC69Q38582650-2FBD6543-7522-44B0-B592-7EF84935A488Q39029195-5AA2C7F0-1FBD-431B-AEA0-57969F8651EEQ39044162-065E7A51-48C9-4354-93CF-B4A612DDC354Q39187610-86A32530-AF47-4D26-947E-E42DC2DE6EC7Q39380445-0812743E-E0BF-47EB-A15A-5A4F698CF64AQ44006947-2798A75C-B135-4D34-8B8F-09FB56F28847Q45073732-525884A1-E0FA-4797-87B6-113E3DD846D1Q47353792-4DB22074-94F0-4B0A-A8B7-C047BC587CEDQ48238170-6AED3AD8-754B-4BF7-B121-098B5DA87912Q50102737-DF48DD79-46E9-4599-A500-6DFF60CE3648Q51876606-3C596E92-B423-46CC-A568-567575BE5150Q57217007-229E0025-A774-40DF-A39E-5A134F9347D9
P2860
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A phase II study of bortezomib ...... inical Trials Group (IND 172).
@ast
A phase II study of bortezomib ...... inical Trials Group (IND 172).
@en
type
label
A phase II study of bortezomib ...... inical Trials Group (IND 172).
@ast
A phase II study of bortezomib ...... inical Trials Group (IND 172).
@en
prefLabel
A phase II study of bortezomib ...... inical Trials Group (IND 172).
@ast
A phase II study of bortezomib ...... inical Trials Group (IND 172).
@en
P2093
P2860
P1433
P1476
A phase II study of bortezomib ...... inical Trials Group (IND 172).
@en
P2093
C Tom Kouroukis
Elizabeth Eisenhauer
Jean Powers
Louis A V Fernandez
Michael Crump
Neil Sun Chua
Rena Buckstein
Richard J Klasa
Robert Turner
Sarit Assouline
P2860
P304
P356
10.3109/10428194.2010.546015
P577
2011-03-01T00:00:00Z